Actinium Pharmaceuticals, Inc. (NYSE:ATNM – Get Free Report)’s stock price fell 3.4% during mid-day trading on Monday. The company traded as low as $1.41 and last traded at $1.43. Approximately 104,552 shares changed hands during trading, a decline of 33% from the average session volume of 155,892 shares. The stock had previously closed at $1.48.
Actinium Pharmaceuticals Trading Up 0.7%
The business has a fifty day moving average of $1.21 and a 200-day moving average of $1.12. The firm has a market cap of $44.33 million, a PE ratio of -1.01 and a beta of 0.26.
Hedge Funds Weigh In On Actinium Pharmaceuticals
Several hedge funds and other institutional investors have recently added to or reduced their stakes in ATNM. BlackRock Inc. bought a new stake in shares of Actinium Pharmaceuticals during the 2nd quarter valued at about $388,000. Renaissance Technologies LLC increased its position in shares of Actinium Pharmaceuticals by 20.7% in the first quarter. Renaissance Technologies LLC now owns 471,600 shares of the company’s stock worth $469,000 after purchasing an additional 80,816 shares during the last quarter. Finally, Compass Financial Management LLC bought a new position in shares of Actinium Pharmaceuticals in the second quarter worth approximately $588,000. 27.50% of the stock is currently owned by hedge funds and other institutional investors.
About Actinium Pharmaceuticals
Actinium Pharmaceuticals, Inc is a biotechnology company focused on developing targeted radiotherapies for patients with hematologic malignancies, particularly those with relapsed or refractory disease. The company’s approach uses monoclonal antibodies to deliver radioactive isotopes directly to cancer cells, with the goal of selectively destroying malignant cells while limiting damage to healthy tissue.
Actinium’s leading investigational product is Iomab-B, also known as iodine-131 apamistamab.
See Also
- Five stocks we like better than Actinium Pharmaceuticals
- Why ExxonMobil and Chevron Reminded Investors to Keep it Simple
- Amazon Has Erased Its Earnings Sell-Off, But Is the Biggest Opportunity Still Ahead?
- onsemi’s AI Sales Surge 175%: Is a Stock Recovery Next?
- Energy Transfer’s Earnings Miss May Be Hiding Its Strongest Advantage
Receive News & Ratings for Actinium Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Actinium Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
